Summary
Five healthy male volunteers received canrenoate-K 200 mg (Sincomen® pro injectione) by intravenous injection and one week later spironolactone 200 mg (Sincomen®-100) orally. Plasma levels and urinary excretion of unchanged canrenone were determined up to 24 h by a specific HPLC method. Following intravenous administration, the maximum plasma level of 2066±876 ng/ml was found after 29±15 min and thereafter the concentration declined with a half-life of 3.7±1.2 h. Total clearance was 4.2±1.7 ml/min·kg. After oral ingestion, the maximum concentration of 177±33 ng/ml was observed at 4.4±0.9 h. The absolute bioavailability of canrenone was 25±9%. Within 24 h, respectively 0.4 and 0.6 mg, canrenone were excreted by the kidney after intravenous and oral administration. The half-life of elimination was 4.9±1.8 h (i.v.) and 3.9±1.2 h (p.o.).
Similar content being viewed by others
References
Karim A, Hribar J, Aksamit W, Doherty M, Chinn L (1975) Spironolactone metabolism in man studied by gas chromatography — mass spectrometry. Drug Metab Dispos 3: 467–478
Karim A, Zagarella J, Hribar J, Dooley M (1976) spironolactone. I. Disposition and metabolism. Clin Pharmacol Ther 19: 158–169
Abshagen U, Rennekamp H, Luszpinski G (1976) Pharmacokinetics of spironolactone in man. Naunyn Schmiedeberg's Arch Pharmacol 296: 37–45
Karim A, Ranney RE, Maibach HJ (1971) Pharmacokinetic and metabolic fate of potassium canrenoate (SC-14266) in man. J Pharm Sci 60: 708
Sadée W, Dagcioglu M, Schöder R (1973) Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther 185 (3): 686–695
Sponer G, Kaufmann G, Kuhr M (1976) Krankenhausarzt 49: 569
Abshagen U, Besenfelder E, Endele R, Koch K, Neubert B (1979) Kinetics of canrenone after single and multiple doses of spironolactone. Eur J Clin Pharmacol 16: 255
Dahlöf CG, Lundborg P, Persson BA, Regardh CG (1979) Reevaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method. Drug Metab Dispos 7 (2): 103
Huston GJ, Turner P, Leighton M (1975) Antagonism of fludrocortisone by spironolactone and canrenone. Br J Clin Pharmacol 3: 201
Ramsay L, Asbury M, Shelton J, Harrison I (1977) Spironolactone and canrenoate-K: Relative potency at steady state. Clin Pharmacol Ther 21: 602
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Krause, W., Karras, J. & Seifert, W. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man. Eur J Clin Pharmacol 25, 449–453 (1983). https://doi.org/10.1007/BF00542109
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542109